Novartis's Sandoz licenses proposed multiple sclerosis biosimilar

The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Lj1bJC
via IFTTT